2 — December 2023 — Nutley Journal
Nutley museum is full of historical treasures (Continued from Page 1) “It was built without closets because she and her husband traveled so much,” explained Tibaldo. There’s also a Narwhal’s tusk that was brought back from the Arctic during Admiral Robert Peary’s expedition in the early 1900s by a former Nutley Mayor Emil Diebitsch who served as Peary’s astronomer. There’s also an old telephone switchboard that was used in Town Hall until the 1980s; and the first Nutley indoor phone booth that was located in Guthrie’s General Store. “That phone was used by Annie Oakley,” said Tibaldo. Books about Nutley and its rich history can be purchased from the Museum store. Titles include “Nutley Yesterday/Today” edited by Ann A. Troy and illustrated by Vivian Noyes Fikus; and “Nutley Notables—The Men and Women Who Made a Memorable Impact on Our Town” by Anthony Buccino. Autographed copies are available. To learn more about the Nutley Historical Society and Museum, visit: https://www.nutleyhistoricalsociety.org/ Museum tours are available upon request by calling 973-667-1528.
The treasures inside the Nutley Museum include this phone booth that was in the township general store and was used by Annie Oakley.
Company lauded by Time for creating treatment for Alzheimer’s disease NUTLEY — A product co-created by a Nutley company has been named one of the Best Inventions of 2023 by TIME. The invention is LEQEMBI, which is the first and only approved treatment for patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease (AD). AD is a type of dementia that affects memory and thinking skills as well as behavior impacting a person's ability to perform daily activities. It is a chronic neurodegenerative disorder that is both progressive and irreversible, affecting millions in the U.S. The treatment was created by Eisai Inc. of Nutley and Biogen Inc. of Cambridge, Mass. and was selected by TIME as one of the Best Inventions of 2023 in the Medical Care category. TIME's annual list of the Best Inventions features "200 extraordinary innovations changing lives." To compile the list, TIME solicited nominations from its editors and correspondents around the world, and through an open online application process, paying special attention to growing fields such as AI, green energy, and sustainability. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition and impact. LEQEMBI, also known as Lecanemab,
is the result of a strategic research alliance between Eisai and BioArctic. It was granted traditional approval by the U.S. Food and Drug Administration (FDA) on July 6. In Japan, Eisai received approval from the Ministry of Health, Labour and Welfare on Sept. 25, to manufacture and market lecanemab as a treatment for slowing progression of MCI and mild dementia due to AD. Eisai has also submitted applications for approval of lecanemab in the European Union, China, Canada, Great Britain, Australia, Switzerland, South Korea and Israel. In China and Israel, the applications have been designated for priority review, and in Great Britain, lecanemab has been designated for the Innovative Licensing and Access Pathway (ILAP), which aims to reduce the time to market for innovative medicines. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen cocommercializing and co-promoting the product and Eisai having final decisionmaking authority.
